Full Press Release Details
Hoth Therapeutics Announces HT-ALZ Therapeutic
Shows Positive Results - Reduce Amyloid in Alzheimer's Disease
Significant decrease
in A seen in an Alzheimer's disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ has
the potential to modify A plaque formation in the brain
NEW YORK, NY January 4, 2022/PR Newswire/
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today
announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.
The research was conducted as part of the company's Sponsored Research Agreement with Washington University in St. Louis. HT-ALZ
is a therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease
AD is a neurodegenerative disease that is characterized
by aggregates of amyloid (A ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical
symptoms of the disease such as dementia. The initial experiments, conducted by Carla Yuede, PhD, Associate Professor of Psychiatry, and
John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine, focused on investigating the effect
of orally administered HT-ALZ to reduce the concentration of A in the brain interstitial fluid, using an established Alzheimer's
Disease mouse model (aged APP/PS1+/- mice). The initial data from these studies shows a significant decrease in A in both male and
female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline A levels, supporting
that HT-ALZ has the potential to modify A plaque formation in the brain and be developed as an AD therapeutic.
"The overall positive result from these
studies is a first step but a big one in the development of HT-ALZ as an Alzheimer's therapeutic," said Stefanie Johns, Chief
Scientific Officer of Hoth Therapeutics, Inc. "HT-ALZ is a unique therapeutic in the AD development space because it is eligible
for streamlined development under the 505(b)(2) pathway, including available safety data. This allows Hoth to reach efficacy clinical
trials faster and bring a new potential treatment for patients with Alzheimer's disease."
these experiments show a reduction in circulating brain A in our model, and we are looking forward to determining how these changes
influence behavior and cognitive function," said Dr. Yuede.
Future research studies to be conducted by Dr.
Cirrito and Dr. Yuede will investigate the effect of HT-ALZ on memory, anxiety, and executive function in the APP/PS1+/- mice model after
chronic dosing with HT-ALZ.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused
to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer
therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers and anaphylaxis and pneumonia. Hoth has also entered into
two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements
for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing
of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product
candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing
and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any
other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy
as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position;
Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues;
Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product
launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and
expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not
place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate,"
"intend," "estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations
reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations,
and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as
a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled
"Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange
Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded
solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to
reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required
Phone: (678) 570-6791